首页 | 本学科首页   官方微博 | 高级检索  
     

抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展
引用本文:王洋,梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展[J]. 医疗保健器具, 2011, 0(2): 312-314
作者姓名:王洋  梁岳培
作者单位:桂林医学院;桂林医学院附属医院心胸外科;
基金项目:广西壮族自治区卫生厅立项课题(编号:Z2010290)
摘    要:血管内皮生长因子通过与相应的受体结合刺激血管内皮细胞增殖和迁移,促进新生血管的生成。表皮生长因子受体的过表达甚至突变与机体多种常见肿瘤的发生和转移有着密切的关系。目前化学疗法治疗非小细胞肺癌已经成为常规的治疗方法,如今急需要另外的方法突破化疗的瓶颈。因此以VEGF和EGFIK为靶点.通过现代分子生物学和遗传学等技术方法在基因及细胞分子水平对其表达、活性及其效应等多个环节进行有效抑制而达到治疗肿瘤的目的,是近年来抗肿瘤治疗新的方法和手段之一。本文就抗VEGF及抗EGFFK靶向治疗方面的研究进展做一综述。

关 键 词:VEGF  EGFR  非小细胞肺癌:靶向治疗

Research Advances of Anti-VEGF and Anti-EGFR as a Target Therapy for Non-Small Cell Lung Cancer
WANG Yang ,LIANG Yuepei. Research Advances of Anti-VEGF and Anti-EGFR as a Target Therapy for Non-Small Cell Lung Cancer[J]. Medicine Healthcare Apparatus, 2011, 0(2): 312-314
Authors:WANG Yang   LIANG Yuepei
Affiliation:WANG Yang 1(Review),LIANG Yuepei 2(Revision)(1Guilin Medical College,Guilin 541004,China,2Department of Cardiothoracic Surgery,the Affiliated Hospital of Guilin Medical College,Guilin 541001,China)
Abstract:Chemotherapy has reached a therapeutic plateau in the treatment of non-small cell lung cancer(NSCLC),and effective,better-tolerated treatment strategies are needed.An improved understanding of the molecular processes underlying tumor biology has led to the development of therapies that target these processes.Intracellular signaling pathways related to the VEGF and EGFR both play a central role in tumorigenesis as well as tumor growth,and are therefore rational targets for anti-cancer drug development.Variou...
Keywords:VEGF  EGFR  NSCLC  Target therapy  
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号